Evidence map›Paper›PMID 25890171›Full record

ArticleMolecular cancer2015

Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.

Rong Kong, Er-bao Zhang, Dan-dan Yin, Liang-hui You, Tong-peng Xu, Wen-ming Chen, Rui Xia, Li Wan, Ming Sun, Zhao-xia Wang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 7 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 7 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Rong KongClinical Medical Examination Center, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, PR China. 31815857@qq.com.
Er-bao ZhangDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, PR China. 273459189@qq.com.
Dan-dan YinCancer Research and Therapy Center, The Second Affiliated Hospital of Southeast University, Nanjing, 210029, Jiangsu, PR China. jsnydandan@sina.com.
Liang-hui YouNanjing Maternity and Child Health Care Institute, Nanjing Maternity and Child Health Care Hospital Affiliated with Nanjing Medical University, Nanjing, 210029, China. 991310547@qq.com.
Tong-peng XuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China. xutongpeng_njmu@163.com.
Wen-ming ChenDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China. chenwenming_njmu@163.com.
Rui XiaDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, PR China. 854620993@qq.com.
Li WanDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Jiangjiayuan Road, Nanjing, 210011, Jiangsu, PR China. 411076921@qq.com.
Ming SunDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, PR China. 504997498@qq.com.
Zhao-xia WangDepartment of Oncology, Second Affiliated Hospital of Nanjing Medical University, Jiangjiayuan Road, Nanjing, 210011, Jiangsu, PR China. zhaoxiawang88@hotmail.com.
Wei DeDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, PR China. dewei@njmu.edu.cn.
Zhi-hong ZhangDepartments of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China. zhihongzhang1003@sina.com.
Nanjing Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CNJiangsu Province Hospital · CNNorthern Jiangsu People's Hospital · CNSoutheast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMounting evidence indicates that long noncoding RNAs (lncRNAs) could play a pivotal role in cancer biology. However, the overall biological role and clinical significance of PVT1 in gastric carcinogenesis remains largely unknown.

methodsExpression of PVT1 was analyzed in 80 GC tissues and cell lines by qRT-PCR. The effect of PVT1 on proliferation was evaluated by MTT and colony formation assays, and cell apoptosis was evaluated by Flow-cytometric analysis. GC cells transfected with shPVT1 were injected into nude mice to study the effect of PVT1 on tumorigenesis in vivo. RIP was performed to confirm the interaction between PVT1 and EZH2. ChIP was used to study the promoter region of related genes.

resultsThe higher expression of PVT1 was significantly correlated with deeper invasion depth and advanced TNM stage. Multivariate analyses revealed that PVT1 expression served as an independent predictor for overall survival (p = 0.031). Further experiments demonstrated that PVT1 knockdown significantly inhibited the proliferation both in vitro and in vivo. Importantly, we also showed that PVT1 played a key role in G1 arrest. Moreover, we further confirmed that PVT1 was associated with enhancer of zeste homolog 2 (EZH2) and that this association was required for the repression of p15 and p16. To our knowledge, this is the first report showed that the role and the mechanism of PVT1 in the progression of gastric cancer.

conclusionsTogether, these results suggest that lncRNA PVT1 may serve as a candidate prognostic biomarker and target for new therapies in human gastric cancer.

Indexed as

AnimalsApoptosisBiomarkers, TumorCarcinogenesisCell LineCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16Enhancer of Zeste Homolog 2 ProteinEpigenomicsG1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansMaleMiceBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPolycomb Repressive Complex 2PVT1 long-non-coding RNA, humanRNA, Long Noncoding

Identifiers

PMID25890171
PMCPMC4399399
OpenAlexW2124996418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.